J.B. Chemicals & Pharmaceuticals enterprise value

Share price at each year-end

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


849	432	453	269	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3.1	1.0	0.0	0.0
0.0	13.8	357	548
−849	−418	−95.7	279

4,159	3,447	3,280	3,029
0.0%	0.4%	10.9%	18.1%
4,148	3,918	3,484	3,149
1,107	1,032	897	696
925	861	759	581
704	902	801	626
704	782	539	−139
703	780	528	−148
0.0	120	261	765

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

JBCHEPHARM

J.B. Chemicals & Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersTORNTPHARM ALKEM IPCALAB SAILIFE NH NEULANDLAB ACUTAAS NATCOPHARM

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
- Cash, Equiv & ST Investments	269.1	452.9	432.2	849.1
+ Minority Interest	0.0	0.0	1.0	3.1
+ Total Debt	548.2	357.1	13.8	0.0
Net Debt (memo)	279.1	-95.7	-418.4	-849.1

Total Capital	3,028.6	3,280.5	3,447.1	4,159.2
Total Debt/Total Capital	18.10	10.89	0.40	0.00
Reference Items — Trailing FY Values
Sales	3,149.3	3,484.2	3,918.0	4,147.8
EBITDA	695.8	896.9	1,031.8	1,107.4
EBIT	581.3	758.6	860.8	924.9
Operating Cash Flow	625.6	800.6	902.5	703.9
Free Cash Flow	-139.3	539.3	782.2	703.9
FCFF (free cash flow to the firm)	-147.8	527.6	779.7	703.2
Capital Expenditure	765.0	261.4	120.3	0.0

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.